货号：M2981

储存条件：粉末-20°C可保存3年；液体-80°C可保存12月。

产品描述

Renal disease in systemic lupus erythematosus carries significant morbidity and mortality. Intensive immunosuppression to dampen kidney inflammation timely and maintenance therapy to prevent renal flares is necessary to reduce the long-term risk of renal failure. Mycophenolate mofetil (MMF) has emerged to be the first-line treatment of lupus nephritis for its better safety profile compared with cyclophosphamide. Low-dose combination of MMF and tacrolimus has been shown to be more efficacious than intravenous pulse cyclophosphamide in inducing remission of lupus nephritis in Chinese patients^[1]. Systemic plasma clearance of intravenous MMF was around 10 L/min in healthy individuals, and plasma MMF concentrations fell below the quantitation limit (0.4 mg/L) within 10 minutes of the cessation of infusion. The pharmacokinetics of patients with renal transplants (after 3 months or more) compared with those of healthy individuals were similar after oral MMF^[2]. Uncontrolled studies in patients with FRNS (frequently relapsing nephrotic syndrome) and SDSN (steroid-dependent nephrotic syndrome) have shown that many patients can achieve sustained remission of proteinuria with MMF monotherapy.

产品信息